Needham Reiterates Buy on G1 Therapeutics, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Gil Blum reiterated a Buy rating on G1 Therapeutics (NASDAQ:GTHX) and maintained an $18 price target.
June 05, 2023 | 9:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reiterated a Buy rating on G1 Therapeutics and maintained an $18 price target.
The reiteration of a Buy rating by Needham analyst Gil Blum on G1 Therapeutics (GTHX) and maintaining an $18 price target indicates a positive outlook for the stock. This news is directly related to GTHX and is important for investors as it reflects the analyst's confidence in the company's potential growth. The score of 1 indicates a likely short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100